A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302

Phase 4 Terminated 5 enrolled Pacira Pharmaceuticals, Inc Registrat-Mapi · collab

Non-randomizedParallel-groupOpen-labelHealth-services research

Summary

This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.

Timeline

Start: 2012-05
Primary completion: 2012-07
Completion: 2012-07

Outcome

Outcome not reported

Stopped (Enrollment): “Slow enrollment.”

Publications

Cohen SM, Vogel JD, Marcet JE, Candiotti KA. Liposome bupivacaine for improvement in economic outcomes and opioid burden in GI surgery: IMPROVE Study pooled analysis. J Pain Res. 2014 Jun 24;7:359-66. doi: 10.2147/JPR.S63764. eCollection 2014.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bupivacaine	Other / unclassified	266 mg	Other
Comparator	Morphine	Other / unclassified	—	Intravenous